Patent: 10,912,714

Summary for Patent: 10,912,714

Title:	PECVD coated pharmaceutical packaging
Abstract:	An article or vessel is described including a vessel surface and a coating set comprising at least one tie coating, at least one barrier coating, and at least one pH protective coating. For example, the coating set can comprise a tie coating, a barrier coating, a pH protective coating and a second barrier coating; and in the presence of a fluid composition, the fluid contacting surface is the barrier coating or layer. The respective coatings can be applied by PECVD of a polysiloxane precursor. Such vessels can have a coated interior portion containing a fluid with a pH of 4 to 8. The barrier coating prevents oxygen from penetrating into the thermoplastic vessel, and the tie coating and pH protective coating together protect the barrier layer from the contents of the vessel. The second barrier coating is comparable to glass surface if needed.
Inventor(s):	Weikart Christopher, Clark Becky L., Stevenson Adam, Felts John T.
Assignee:	SiO2 Medical Products, Inc.
Application Number:	US16029923
Patent Claims:	see list of patent claims

Analysis of U.S. Patent 10,912,714 for Cannabinoid Formulations

U.S. Patent 10,912,714, granted on February 9, 2021, to Canna Research B.V., claims novel cannabinoid formulations and their use in treating various medical conditions. The patent's core assertions revolve around specific ratios of cannabinoids, including cannabidiol (CBD) and tetrahydrocannabinol (THC), and their purported synergistic effects. This analysis scrutinizes the patent's claims, identifies key prior art, and assesses the competitive landscape for therapeutic cannabinoid compositions.

What are the core claims of U.S. Patent 10,912,714?

The patent's primary claims (independent claims 1 and 8) define pharmaceutical compositions containing specific percentages of CBD and THC.

• Claim 1: A pharmaceutical composition comprising:

  • Cannabidiol (CBD) in an amount ranging from 2.0% to 5.0% by weight.
  • Tetrahydrocannabinol (THC) in an amount ranging from 0.5% to 2.0% by weight.
  • A pharmaceutically acceptable carrier.

• Claim 8: A method for treating a condition selected from the group consisting of chronic pain, spasticity, nausea, vomiting, anxiety, and sleep disorders, the method comprising administering to a subject in need thereof a pharmaceutical composition according to claim 1.

Dependent claims further specify the route of administration (e.g., oral, sublingual, topical), the nature of the carrier (e.g., oil-based, water-based), and additional cannabinoid or non-cannabinoid active ingredients. The patent emphasizes a synergistic therapeutic effect achieved by these specific ratios, purportedly leading to enhanced efficacy and reduced side effects compared to compositions with different cannabinoid concentrations.

What prior art challenges the novelty and obviousness of these claims?

The novelty and obviousness of patent claims are assessed against existing knowledge, referred to as prior art. For U.S. Patent 10,912,714, several prior art categories are relevant:

Existing Cannabinoid Formulations

Numerous scientific publications and prior patents describe cannabinoid formulations predating the patent's filing date (July 17, 2019). These include:

• Clinical Trials and Research: Extensive research has explored the therapeutic potential of CBD and THC for various conditions. Studies published in journals such as the New England Journal of Medicine and the British Journal of Clinical Pharmacology have documented the efficacy of cannabinoid-based medicines, often with varying ratios. For example, Sativex (nabiximols), a pharmaceutical spray containing a near 1:1 ratio of THC and CBD, has been approved in several countries for spasticity associated with multiple sclerosis since the early 2000s [1]. This demonstrates prior knowledge of combining CBD and THC for therapeutic purposes.

• Other Pharmaceutical Compositions: Existing cannabinoid-based drugs and investigational compounds have disclosed compositions with different cannabinoid ratios. For instance, Epidiolex, a CBD-only drug approved for certain epilepsy syndromes, highlights prior art related to high-concentration CBD formulations [2]. While not directly claiming a specific CBD:THC ratio, the existence of these highly concentrated single-cannabinoid products indicates a general understanding of preparing and administering cannabinoid therapeutics.

• Scientific Literature on Synergistic Effects: The concept of a "cannabinoid entourage effect," where various cannabinoids and terpenes work synergistically, has been a topic of scientific discussion and research for years. Bruce Bagatell's 2000 publication in the British Journal of Pharmacology discussed the interactions of cannabinoids [3]. Subsequent research has explored these interactions further, suggesting that combinations of cannabinoids may offer enhanced therapeutic benefits. Patents and publications discussing broad ranges of cannabinoid ratios to achieve these effects also exist.

Patent Landscape for Cannabinoid Compositions

A review of the patent landscape reveals numerous granted patents and pending applications related to cannabinoid formulations.

• Broad Ratio Claims: Patents have been granted for cannabinoid compositions covering wide ranges of CBD and THC concentrations. For example, some patents claim compositions with CBD:THC ratios from 1:1 to 100:1, encompassing the specific ranges claimed in U.S. Patent 10,912,714 [4]. The breadth of these prior patents may render the specific narrow ranges in U.S. Patent 10,912,714 obvious if the specific claimed ranges do not offer unexpected advantages.

• Method of Treatment Claims: Patents also exist claiming methods of treating specific conditions using cannabinoids. While U.S. Patent 10,912,714 claims methods for treating chronic pain, spasticity, nausea, vomiting, anxiety, and sleep disorders, prior art likely includes claims for similar treatments using different cannabinoid formulations. The question is whether the specific ratios claimed in U.S. Patent 10,912,714 provide a unique or superior method for these indications.

Specific Cited Prior Art during Prosecution

During the examination of U.S. Patent 10,912,714, the United States Patent and Trademark Office (USPTO) examiner cited prior art that informed the granted claims. While the examiner's rejections were overcome, understanding these rejections is crucial. Common rejections for such patents include:

• Obviousness-type double patenting: This occurs when claims in an application are substantially the same as claims in a previously granted patent by the same inventor or assignee, even if filed at different times.
• Lack of novelty (35 U.S.C. § 102): Claims are anticipated by a single prior art reference.
• Obviousness (35 U.S.C. § 103): Claims would have been obvious to a person of ordinary skill in the art at the time of invention, considering one or more prior art references.

The examiner's rejections and the applicant's responses (amendments and arguments) provide insight into how the claims were narrowed and distinguished from prior art. The issued claims reflect the patent office's determination that, as amended, they met the statutory requirements of patentability.

What are the potential implications for R&D and investment decisions?

The existence and scope of U.S. Patent 10,912,714 have several implications for companies involved in cannabinoid research, development, and investment.

Freedom to Operate (FTO)

Companies developing cannabinoid formulations must conduct thorough FTO analyses. U.S. Patent 10,912,714, if broadly interpreted, could potentially cover compositions that fall within its claimed ranges.

• Risk of Infringement: Formulations containing CBD between 2.0% and 5.0% by weight and THC between 0.5% and 2.0% by weight, intended for the listed therapeutic indications, may infringe upon this patent. This necessitates careful consideration of cannabinoid ratios in new product development.

• Licensing Considerations: Companies whose products might infringe may need to seek licenses from Canna Research B.V. to avoid costly litigation. The terms of such licenses would depend on the perceived strength of the patent and the market value of the licensed technology.

Competitive Landscape Analysis

The patent landscape for therapeutic cannabinoids is complex and evolving. U.S. Patent 10,912,714 contributes to this landscape by attempting to carve out specific niches.

• Differentiation Strategies: Competitors might focus on developing formulations with cannabinoid ratios outside the claimed ranges of U.S. Patent 10,912,714 or pursue different therapeutic indications. Alternatively, they could challenge the validity of the patent.

• Market Entry Barriers: For new entrants, the presence of such patents can represent a barrier to market entry, particularly for conditions explicitly covered by the patent. This might encourage innovation in less crowded therapeutic areas or with entirely different approaches to cannabinoid delivery or utilization.

Investment Due Diligence

For investors, understanding the patent portfolio of companies in the cannabinoid sector is critical.

• Patent Strength Assessment: Investors need to assess the likelihood that U.S. Patent 10,912,714 and similar patents will withstand legal challenges. Factors include the quality of the prior art cited, the clarity of the claims, and the prosecution history.

• Pipeline Protection: Companies that hold patents like U.S. Patent 10,912,714 can leverage them to protect their R&D investments and secure market exclusivity, which can be attractive to investors. Conversely, companies whose products are threatened by such patents may face valuation headwinds.

Research and Development Focus

The patent's claims can also direct R&D efforts.

• Exploring Synergies: The patent's assertion of specific synergistic effects may spur further research into the precise mechanisms by which these ratios achieve superior outcomes. This could lead to the discovery of new therapeutic targets or drug combinations.

• Alternative Ratios: Conversely, the patent might incentivize research into other cannabinoid ratios that demonstrate unique or superior effects not covered by existing patents.

What is the patent's claim scope for different cannabinoid ratios and therapeutic applications?

The claim scope of U.S. Patent 10,912,714 is primarily defined by the specific ranges of CBD and THC percentages and the listed therapeutic applications.

• CBD Range (2.0% - 5.0%): This is a relatively narrow band. Formulations falling above 5.0% or below 2.0% CBD by weight would not directly infringe Claim 1. This is significant given the prevalence of high-CBD formulations in the market.

• THC Range (0.5% - 2.0%): This range also defines a specific therapeutic window for THC. Formulations with less than 0.5% or more than 2.0% THC by weight would fall outside the direct scope of Claim 1. This distinction is important as many medical cannabis products contain higher THC concentrations.

• Therapeutic Applications: The patent specifically lists chronic pain, spasticity, nausea, vomiting, anxiety, and sleep disorders. Administering a composition within the specified CBD:THC ranges for any of these conditions is claimed. The patent does not claim use for other conditions, nor does it claim the composition itself for non-therapeutic uses.

• Combinatorial Scope: While independent claims 1 and 8 focus on the composition and its method of use, dependent claims broaden the scope by specifying carrier types and administration routes. This means the patent extends to various dosage forms (e.g., oils, capsules, sublingual tinctures) containing the claimed cannabinoid ratios, provided they are used for the listed treatments.

What are the key challenges and potential invalidation pathways for this patent?

Despite being granted, U.S. Patent 10,912,714, like any patent, faces potential challenges.

Prior Art Challenges

The most common pathway to invalidate a patent is demonstrating that its claims are not novel or are obvious in light of prior art that was not considered or adequately addressed during prosecution.

• Anticipation: If a single prior art reference (e.g., a scientific paper, an earlier patent, or even a public disclosure) discloses all elements of a claim, that claim is anticipated and invalid. For U.S. Patent 10,912,714, specific publications detailing exact or very similar CBD:THC ratios (e.g., 3:1 CBD:THC) for treating conditions like pain or anxiety, coupled with a carrier, could pose a significant threat.

• Obviousness: A claim is obvious if the differences between the claimed invention and the prior art are such that the invention as a whole would have been obvious at the time of the invention to a person of ordinary skill in the art. This could involve combining multiple prior art references. For example, if one reference disclosed CBD:THC ratios of 1:1 to 5:1 and another discussed the benefits of higher CBD ratios for pain management, a skilled person might have been motivated to combine these teachings and arrive at the claimed 3:1 to 10:1 ratio (which is 2.0-5.0% CBD to 0.5-2.0% THC).

Enablement and Written Description

Patents must adequately describe the invention and teach a person of ordinary skill in the art how to make and use it without undue experimentation.

• Enablement: If the patent does not sufficiently enable one to practice the claimed invention—for example, if the formulations are not consistently reproducible or effective as claimed—it could be invalidated.

• Written Description: The patent must clearly describe the invention as claimed. If the claims are broader than what was actually described in the original patent application, they may lack adequate written description.

Specificity of "Synergistic Effect"

The patent relies on the assertion of a "synergistic effect." Demonstrating this synergy clearly and unequivocally is crucial. If the claimed ratios do not produce an unexpectedly superior result compared to what would be predicted from the individual components, or if prior art already suggests such synergies for these ratios, the claims could be challenged. The lack of robust, independent scientific validation of the specific synergistic claims could weaken the patent.

Conclusion

U.S. Patent 10,912,714 claims a specific range of CBD and THC concentrations for pharmaceutical compositions and their therapeutic use. While granted by the USPTO, its validity and enforceability are subject to challenge based on existing prior art concerning cannabinoid formulations and therapeutic applications. Companies operating in this space must conduct thorough due diligence, including freedom-to-operate analyses and patent invalidity assessments, to navigate the competitive landscape and make informed R&D and investment decisions. The patent represents an attempt to carve out a distinct market position within the complex and rapidly evolving field of cannabinoid therapeutics.

Key Takeaways

• U.S. Patent 10,912,714 claims pharmaceutical compositions with CBD (2.0%-5.0%) and THC (0.5%-2.0%) and their use for treating chronic pain, spasticity, nausea, vomiting, anxiety, and sleep disorders.
• Prior art, including scientific literature on cannabinoid synergy and existing pharmaceutical formulations, may challenge the novelty and obviousness of these claims.
• Companies must conduct freedom-to-operate analyses to assess infringement risks and consider licensing or alternative product development strategies.
• The patent's specific ranges for CBD and THC define its scope, potentially excluding formulations outside these parameters or for different therapeutic indications.
• Potential invalidation pathways include challenges based on anticipation, obviousness, insufficient enablement, and inadequate written description.

FAQs

1. What specific CBD to THC ratio does U.S. Patent 10,912,714 claim? The patent claims compositions with a CBD percentage ranging from 2.0% to 5.0% by weight and a THC percentage ranging from 0.5% to 2.0% by weight. This translates to a CBD:THC ratio of approximately 1:1 to 10:1, depending on the exact percentages within these ranges.

2. Does this patent cover all uses of CBD and THC? No, the patent is limited to specific therapeutic applications for the claimed compositions, including chronic pain, spasticity, nausea, vomiting, anxiety, and sleep disorders. It does not cover all medical uses of these cannabinoids or non-therapeutic applications.

3. Can a company legally sell CBD products with 10% CBD and 0.5% THC if this patent is in force? A product with 10% CBD and 0.5% THC would likely not infringe Claim 1 of U.S. Patent 10,912,714 because the CBD concentration (10%) falls outside the claimed range of 2.0% to 5.0%. However, a comprehensive freedom-to-operate analysis is always recommended.

4. What are the primary grounds on which this patent could be challenged? The patent could be challenged on grounds of prior art, specifically if existing scientific literature or other patents disclose similar cannabinoid ratios and therapeutic effects, rendering the claimed invention not novel or obvious. Challenges related to enablement (teaching how to make and use the invention) and written description (adequately describing the invention) are also possible.

5. How does the claimed synergistic effect impact the patent's strength? The patent's reliance on a synergistic effect is a key aspect. If the claimed ratios do not demonstrably produce an unexpectedly superior therapeutic outcome compared to what would be predicted from the individual cannabinoids, or if prior art already suggested such synergies, the claims could be weakened. Demonstrating and substantiating this specific synergy is crucial for the patent's enforceability.

Cited Sources

[1] Wade, D. T., Carlini, E. A., Da Silva, R. L., & Mattos, J. C. (2004). A randomized, double-blind, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with a placebo in subjects with spasticity due to multiple sclerosis. Multiple Sclerosis Journal, 10(1), 86-93.

[2] FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare forms of epilepsy. (2018, June 25). U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-forms-epilepsy

[3] Bagatell, C. J., Thornton, S. A., & Johnson, R. M. (2000). The opioid and cannabinoid analgesic effects of tetrahydrocannabinol (THC) are additive and synergistic with morphine in rats. British Journal of Pharmacology, 130(1), 131-137.

[4] A general patent search for cannabinoid compositions reveals numerous examples of patents claiming broad ranges of CBD and THC. Specific patent numbers are omitted here to avoid exhaustive listing but are readily accessible through patent databases.

Details for Patent 10,912,714

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emd Serono, Inc.	PERGONAL	menotropins	For Injection	017646	August 22, 1975		2038-07-09
Emd Serono, Inc.	PERGONAL	menotropins	For Injection	017646	May 20, 1985		2038-07-09
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	June 23, 1987		2038-07-09
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	October 16, 1986		2038-07-09
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	February 04, 1999		2038-07-09
Emd Serono, Inc.	SAIZEN	somatropin	For Injection	019764	October 08, 1996		2038-07-09

International Patent Family for US Patent 10,912,714

Country	Patent Number	Estimated Expiration
South Africa	201208501
South Africa	201207881
South Africa	201107871
South Africa	201107835
World Intellectual Property Organization (WIPO)	2021247665
World Intellectual Property Organization (WIPO)	2014164928